Previous close | 2.6100 |
Open | 2.6400 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 800 |
Day's range | 2.6400 - 2.8100 |
52-week range | 1.6000 - 5.9800 |
Volume | |
Avg. volume | 576,938 |
Market cap | 138.521M |
Beta (5Y monthly) | 1.46 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 31 Oct 2014 |
1y target est | N/A |
Participants on today's call are Evan Loh, M.D., chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer. Michael Bigham, executive chairman, and I will also be available for questions.
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The big shareholder groups in Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) have power over the company. Large...